A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep

Chen, Weiye; Hu, Sen; Qu, Linmao; Hu, Qianqian; Zhang, Qian; Hai-bing, Zhi; Huang, Kehe; Bu, Zhigao

doi:10.1016/j.vaccine.2010.04.102

Cited by 80 publications

(62 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multivalent vaccines are currently being developed that may both protect vaccinated animals against several viral pathogens and enable vaccinated and infected animals to be distinguished using DIVA tests. Currently, vaccines exist based on the incorporation of PPRV immunogens into vectors such as sheep and goat pox (Berhe et al, 2003;Chaudhary et al, 2009;Chen et al 2010;Diallo et al, 2002) and attempts are also being made to develop new vaccines based on recombinant DNA technology .…”

Section: Pprv: Diagnosis Prevention and Future Controlmentioning

confidence: 99%

Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control

Banyard¹,

Parida

Batten

et al. 2010

Journal of General Virology

361

420

View full text Add to dashboard Cite

Section: Pprv: Diagnosis Prevention and Future Controlmentioning

confidence: 99%

Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control

Banyard¹,

Parida

Batten

et al. 2010

Journal of General Virology

361

420

View full text Add to dashboard Cite

“…This is especially useful in situations where surveillance is being implemented at the same time as vaccination. In recent years several such vaccines have been successfully developed, particularly using adenovirus [52][53][54][55] and goat/ sheep pox vectors [56][57][58], and some have been tested for efficacy in conventional PPR challenge studies; however, their capacity for long-term protection (up to 2 years) has yet to be determined. For vectored vaccines, the presence of pre-existing immunity against the vector, i.e.…”

Section: Development and Application Of Pprv Vaccinesmentioning

confidence: 99%

Future research to underpin successful peste des petits ruminants virus (PPRV) eradication

Baron

Diop

Njeumi

et al. 2017

Journal of General Virology

View full text Add to dashboard Cite

Peste des petits ruminants virus (PPRV) is a significant pathogen of small ruminants and is prevalent in much of Africa, the Near and Middle East and Asia. Despite the availability of an efficacious and cheap live-attenuated vaccine, the virus has continued to spread, with its range stretching from Morocco in the west to China and Mongolia in the east. Some of the world's poorest communities rely on small ruminant farming for subsistence and the continued endemicity of PPRV is a constant threat to their livelihoods. Moreover, PPRV's effects on the world's population are felt broadly across many economic, agricultural and social situations. This far-reaching impact has prompted the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE) to develop a global strategy for the eradication of this virus and its disease. PPRV is a morbillivirus and, given the experience of these organizations in eradicating the related rinderpest virus, the eradication of PPRV should be feasible. However, there are many critical areas where basic and applied virological research concerning PPRV is lacking. The purpose of this review is to highlight areas where new research could be performed in order to guide and facilitate the eradication programme. These areas include studies on disease transmission and epidemiology, the existence of wildlife reservoirs and the development of next-generation vaccines and diagnostics. With the support of the international virology community, the successful eradication of PPRV can be achieved.

show abstract

“…However, DIVA vaccine candidates would need to be evaluated in comparison with conventional vaccines for the full range of vaccine attributes (e.g., efficacy, impact on virus shedding and transmission, duration of immunity, range of protection, safety, minimum dose, ease of production, cost) in addition to diagnostic advantages. Candidate vaccines for DIVA technologies include capripox (30,31) and adenovirusvectored vaccines (18,32). Prior exposure to capripox reduced the immune responses to the PPR Ags in vaccinates and, in the one study where challenge was carried out, incomplete protection against clinical disease.…”

Section: Suitable Vaccines and Diagnostics Are Availablementioning

confidence: 99%

The Opportunity To Eradicate Peste des Petits Ruminants

Mariner

Jones

Rich

et al. 2016

The Journal of Immunology

View full text Add to dashboard Cite

Peste des petits ruminants (PPR) is a highly infectious disease of sheep and goats that is caused by PPR virus, a member of the genus Morbillivirus that includes the viruses that cause rinderpest (RP) in cattle. RP was the first animal disease to be globally eradicated in 2011 and is only the second disease, after smallpox, to have ever been eradicated. PPR is one of the principal constraints to small ruminant production in Africa, Asia, and the Middle East. The epidemiology of PPR and RP as well as the technologies available for their diagnosis and control are similar. The conditions that favored the eradication of RP are also largely present for PPR. In this work, we outline the evolving strategy for eradication in light of current opportunities and challenges, as well as the lessons from other eradication programs in animal and human health. The global PPR situation and technology for its control are summarized. A strategy based on the lessons from previous eradication efforts that integrate epidemiology, social science, and economics as tools to target and motivate vaccination is summarized. Major aspects of the cost and benefit-cost analysis of the indicated program are presented. The overall undiscounted cost of eradication was estimated as $3.1 billion, and the benefit-cost ratio for the most likely scenario was estimated at 33.8. We close with a discussion of the possible next steps.

show abstract

A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep

Cited by 80 publications

References 43 publications

Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control

Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control

Future research to underpin successful peste des petits ruminants virus (PPRV) eradication

The Opportunity To Eradicate Peste des Petits Ruminants

Contact Info

Product

Resources

About